Request in writing
- Screening criteria and exclusion criteria
- ECG/QTc process and review plan
- Electrolyte and liver-function testing process
- Medication and substance interaction review
Ibogaine treatment in Baja
Safety Checklist
A practical, evidence-aware set of questions for prospective patients, families, and referring clinicians considering ibogaine in Baja.
Safety is not a promise. It is a set of documented decisions, resources, and contingency plans.
Start before travel
Begin with the questions that can change the decision.
Ibogaine can present significant medical risk. A safety review should not begin with setting or testimonials; it should begin with individual risk factors, provider documentation, and whether emergency capabilities are genuinely available. For broader context on the questions that shape a cross-border decision, the main safety resource outlines a careful, plain-language approach.
People comparing programs should expect clear discussion of screening, monitoring, transfer logistics, and follow-up. This brief does not offer dosing recommendations or make therapeutic claims. Its purpose is to help identify the information that should be available before a person travels or proceeds.
Before treatment
Ask for a complete medical screen—not a quick clearance.
Cardiac history deserves particular attention. Request a current ECG and a documented QTc review, along with an explanation of how a finding would affect eligibility. The clinical overview of long QT syndrome describes why QT prolongation is treated as a serious arrhythmia concern.
Ask how electrolytes and liver function are assessed and what happens when results are abnormal. Potassium, magnesium, and other electrolyte disturbances can matter in a cardiac-risk discussion. Screening should also cover past fainting, seizures, structural heart disease, family history of sudden cardiac death, and any recent illness that could complicate care.
A full medication and substance review is essential. This includes prescribed drugs, over-the-counter products, supplements, alcohol, stimulants, opioids, and benzodiazepines. Opioid and benzodiazepine exposure should not be handled casually: withdrawal, sedation, interaction risk, and timing all require individualized medical judgment. The FDA’s benzodiazepine safety information notes the risks associated with these medicines, including dependence and withdrawal concerns.
Pause for red flags
- Unexplained cardiac symptoms or concerning history
- Abnormal ECG/QTc or unresolved electrolyte issues
- Unclear medication changes or withdrawal plan
- Pressure to proceed without records or questions answered
During care
On-site safeguards should be specific and observable.
Ask who is medically responsible on site, how physician oversight is provided, and whether continuous ECG or telemetry is used for the period in which cardiac complications are a concern. “Medical supervision” is too vague unless the provider can describe staffing, monitoring, escalation, and handoff procedures.
Clarify whether ACLS-ready staff are present, whether IV access is available, how electrolyte repletion is handled, and whether naloxone is immediately available. Naloxone is an opioid-overdose reversal medication; the CDC’s explanation of naloxone describes its role in responding to an opioid overdose, not as a substitute for comprehensive monitoring.
Records should show what is monitored, how often observations are documented, and what thresholds trigger medical escalation. If the explanation relies on reassuring language rather than operational detail, treat that as a reason to slow down.
Emergency readiness
Transfer planning has to work across a border.
Emergency readiness is more than saying a hospital is nearby. Ask which U.S. or Mexican hospitals may receive a transfer, who calls for transport, how long the route may take, what records accompany the patient, and how a family member or support person is included. A cross-border plan should be concrete before treatment begins.
Request documentation of the escalation pathway: the symptoms or monitoring findings that trigger it, available transport arrangements, communication steps, and how care is coordinated if transfer occurs. A provider should be able to explain this plainly without minimizing the possibility of complications.
Named route
Ask for the destination options and the practical route for emergency transport, rather than accepting a general assurance that a hospital is accessible.
Clinical handoff
Confirm what medical records, medication details, monitoring notes, and contact information would travel with the patient.
Support-person role
Clarify who informs family or a support person, how consent questions are handled, and what happens if the patient cannot communicate.
Safety-first review“A plan is only useful when it explains what happens if things do not go as hoped.”
Aftercare
Follow-up should be structured before the treatment day.
Ask what the next days and weeks look like: medication reconciliation, follow-up contacts, transport and lodging considerations, a return-home plan, and support for the period after treatment. The plan should identify who is responsible for each part and what information is provided to an existing clinician, when appropriate.
There should be no pressure to treat aftercare as an optional add-on. It is part of responsible planning, especially when treatment occurs away from home. The site’s what-to-expect guidance can help frame practical questions about preparation, travel, and follow-through.
For people also assessing claims made around neurologic conditions, the independent material on ibogaine treatment for Parkinson’s is best approached with the same evidence-aware caution: ask what is known, what is uncertain, and what risks remain relevant to the individual.
Practical questions
Use uncertainty as a reason to ask for clarity.
What documentation should be requested before travel?
Request the screening criteria, a written account of monitoring and emergency resources, medication and substance review procedures, transfer arrangements, and the aftercare plan. A provider that cannot explain these items in writing creates uncertainty that should be resolved before travel.
What makes emergency transfer planning important?
When care is cross-border, the practical route to a hospital matters: who initiates transfer, where the patient would go, how records travel, and how accompanying people are involved. These questions should be answered before treatment rather than during a crisis.
Why should aftercare be discussed before treatment?
A structured plan should identify medication reconciliation, follow-up contacts, a safer return home, and support for the period after treatment. It should be concrete enough for the patient and family to understand what happens next.
Proceed only when the safety picture is clear.
If basic questions about eligibility, monitoring, escalation, transfer, or follow-up cannot be answered directly, pause. The principles behind this checklist align with the site’s independent approach to safety questions: careful review, plain language, and informed consent before promises.